# NB Private Equity Partners Limited

# **CONTACT INFORMATION**

For questions about NBPE, please contact the Investor Relations department of the Investment Manager at the phone number or email address listed below:

#### **INVESTMENT MANAGER**

NB Alternatives Advisers LLC 325 N. Saint Paul Street Suite 4900 Dallas, TX 75201 United States of America IR NBPE@nb.com Tel. +1.214.647.9593 Fax. +1.214.647.9501

# **REGISTERED OFFICE**

NB Private Equity Partners Limited P.O. Box 225 Heritage Hall, Le Marchant Street St. Peter Port, Guernsey GY1 4HY Channel Islands www.nbprivateequitypartners.com Tel. +44-(0)1481.716.000 Fax. +44-(0)1481.728.452

#### **ORDINARY SHARE INFORMATION**

Trading Symbol: NBPE Exchanges: Euronext Amsterdam & London Stock Exchange Euronext Admission Date: 25 July 2007 LSE Admission Date: 30 June 2009 Base Currency: USD Bloomberg: NBPE NA, NBPE LN Reuters: NBPE.AS, NBPE.L ISIN: GG00B1ZBD492

**ZDP SHARE INFORMATION** 

COMMON: 030991001

Trading Symbol: NBPZ Exchanges: London Stock Exchange & Channel Islands Stock Exchange Admission Date: 1 December 2009 Base Currency: GBP Bloomberg: NBPEGBP LN Reuters: NBPEO.L ISIN: GG00B4ZXGJ22 SEDOL: B4ZXGJ2

Final Capital Entitlement: 169.73 pence

GRY at Issuance: 7.30% Share Life: 7.5 Years to 31 May 2017

As of 29 February 2012, the private equity portfolio included exposure to 75 investments and over 2,500 underlying portfolio companies.

\* Includes both equity and debt investments. \*\* As of 29 February 2012, there were 49,243,696 class A ordinary shares and 10,000 class B ordinary shares outstanding, with 3,150,408 class A ordinary shares held in treasury. As of 31 January 2012, there were 49,275,809 class A ordinary shares and 10,000 class B ordinary shares outstanding,

\*\*\* As of 29 February 2012 and 31 January 2012, there were 32,999,999 ZDP shares outstanding.

with 3,150,408 class A ordinary shares held in

29 February 20121

# **COMPANY OVERVIEW**

NB Private Equity Partners Limited ("NBPE" or "the Company") is a closed-end investment company registered under the laws of Guernsey managed by NB Alternatives Advisers LLC (the "Investment Manager"), an indirect wholly owned subsidiary of Neuberger Berman Group LLC. NBPE invests in private equity funds managed by leading sponsors, including funds of funds managed by the Investment Manager, and makes direct private equity investments alongside leading sponsors ("co-investments"). NBPE's investment objective is to produce attractive returns on its capital from its private equity investments while managing investment risk through portfolio diversification across asset class, vintage year, geography, industry, and sponsor.

# **INVESTMENT MANAGER COMMENTARY**

During February, under the previously announced NB Alternatives direct co-investment program, NBPE funded two mid-cap buyout co-investments, one in ADPI, a provider of dental practice management and the other in Blue Coat, a provider of web security and network optimization appliances and services.

In addition, NBPE committed \$50 million to the NB Athyrium drug royalty investment program. The drug royalty investment program is an attractive opportunity because many companies lack the ability to obtain traditional sources of financing, yet have strong products or treatments backing the royalty notes. In addition, the Company believes income streams from these yielding investments have the added characteristic of generally being less correlated to the overall economy. In February, as part of the NB Athyrium drug royalty program, NBPE funded a special situation direct investment in royalty backed notes that are collateralized by the sale of medication delivery and blood collection products.

Including new investment activity, NBPE invested \$42.5 million into private equity investments and received \$8.4 million of distributions during February. As a result of this investment activity, the Company's private equity investment level was 107% of NAV at 29 February 2012. Approximately 88% of the contributions were invested in buyout co-investments, 9% were invested in special situation co-investments, 2% were invested in special situation funds, and 1% was invested in growth equity/venture funds. A majority of the distributions during the month were from fund investments in Platinum Equity Capital Partners II and Avista Capital Partners.

As of 29 February 2012, the unaudited NAV per share was \$11.20, which represents an increase of 0.6% compared to the unaudited restated NAV per share of \$11.13 at 31 January 2012. During February, NBPE's portfolio value increased due to \$2.3 million of unrealized gains on public securities, \$2.1 million of unrealized gains on credit-related fund investments, and \$0.5 million of positive foreign exchange adjustments. Share repurchases during the month were accretive to NAV per share by approximately \$0.01.


# **NET ASSET VALUE DEVELOPMENT**


(\$ in millions, except per share data)		
Summary of NAV of Ordinary Shares	29 February 2012 (Unaudited)	31 January 2012 (Unaudited, restated)
Fund Investments and Fund of Funds Investments	\$409.6	,
Direct / Co-investments *	*	\$410.9
	\$178.7	\$ 138.4
Total Private Equity Investments	\$588.3	\$549.3
Cash and Cash Equivalents	\$37.2	\$71.9
Credit Facility Outstanding	-	-
ZDP Share Liability, incl. Forward Currency Contract	(\$63.2)	(\$62.9
Net Other Assets (Liabilities), incl. M inority Interest	(\$10.9)	(\$9.9
Net Asset Value	\$ 551.4	\$548.4
Net Asset Value per Share **	\$ 11.20	\$ 11.13
Closing Share Price (Euronext Amsterdam)	\$6.99	\$6.93
Premium (Discount)	(37.6%)	(37.7%)
Summary of Private Equity Exposure		
Estimated Fair Value of Private Equity Investments	\$588.3	\$549.3
Unfunded Private Equity Commitments	\$310.9	\$301.7
Total Private Equity Exposure	\$899.2	\$851.0
Private Equity Investment Level	107%	100%
Cash + Undrawn Committed Credit Facility	\$287.2	\$321.9
Commitment Cover Ratio	92%	107%
(In £)		
Summary of the ZDP Shares		
ZDP Net Asset Value per Share ***	117.18p	116.53p
Closing ZDP Share Price (LSE)	13 1.75 p	131.75p
Premium (Discount)	12.4%	13.1%


29 February 20121


# PRIVATE EQUITY PORTFOLIO DIVERSIFICATION

Key information about NBPE's private equity portfolio based upon fair value at 29 February 2012 was as follows.<sup>2</sup>









Based on total private equity exposure, which includes unfunded commitments, the diversification of NBPE's private equity portfolio at 29 February 2012 was as follows: <sup>2</sup>

- Asset class and investment type special situations funds: 30%; special situations direct investments: 5%; mid-cap buyout funds: 19%; mid-cap buyout co-investments: 15%; large-cap buyout funds: 9%; large-cap buyout co-investments: 7%; growth / venture: 10%; secondary purchases: 5%
- Geography North America: 78%; Europe: 17%; Asia / rest of world: 5%
- Industry energy / utilities: 11%; financial services: 11%; consumer / retail: 9%; industrials: 13%; communications / media: 7%; technology / IT: 9%; healthcare: 9%; business services: 3%; transportation: 5%; diversified / undisclosed / other: 23%

The diversification of NBPE's unfunded private equity commitments at 29 February 2012 was as follows: <sup>2</sup>

- Asset class and investment type special situations funds: 35%; mid-cap buyout funds: 25%; mid-cap buyout co-investments: 1%; large-cap buyout funds: 6%; growth / venture: 25%; secondary purchases: 8%
- Vintage year of fund or direct / co-investment 2004 & Earlier: 2%; 2005: 1%; 2006: 13%; 2007: 43%; 2008: 5%; 2009: 10%; 2010: 17%; 2011: 9%

#### 29 February 2012<sup>1</sup>

# **VALUATION METHODOLOGY**

The Company carries its private equity investments on its books at fair value using the best information it has reasonably available to determine or estimate fair value. Publicly traded securities are valued based on quoted prices as of the last day of the relevant period less discounts to reflect legal restrictions, if any, that affect marketability. The Company determines such values for publicly traded securities held directly as well as known public positions held in the underlying private equity investments on a look-through basis. The Company estimates fair value for private interests based on a methodology that begins with the most recent information available from the general partner of the underlying fund or the lead investor of a direct co-investment, and considers subsequent transactions, such as drawdowns or distributions, as well as other information judged to be reliable that reports or indicates valuation changes, including realizations and other portfolio company events. The Company proactively revalues its investments before it has received updated information from the fund manager or lead sponsor if it becomes aware of material events that justify a change in valuation. If the Company concludes that it is probable an investment will be sold, the Company will adjust the carrying value to the amount the Company expects to realize from the sale, exclusive of transaction costs.

# TRADING VOLUME AND SHARE REPURCHASE ACTIVITY

During the month of February, NBPE's aggregate trading volume on Euronext Amsterdam, the London Stock Exchange, and over-the-counter trading platforms was 476,346 shares, which represents an average daily trading volume of approximately 22,683 shares. The trading volume in February included approximately 101,509 shares traded over-the-counter and not reported on Euronext Amsterdam or the London Stock Exchange.

On 22 October 2010, we launched a new Share Buy-Back Programme in order to begin implementing the Capital Return Policy. The Share Buy-Back Programme was extended on 30 August 2011, 29 November 2011, and 9 March 2012, subject to further extension, will end on 31 May 2012. Under the terms of the Share Buy-back Programme, Jefferies International Limited ("JIL") has been appointed to effect on-market repurchases of Shares on behalf of NBPE on Euronext Amsterdam and/or the Specialist Fund Market of the London Stock Exchange<sup>1</sup>. Shares bought back under the Share Buy-Back Programme will be cancelled.

During February, a total of 32,113 shares were repurchased under the Programme at an aggregate net purchase price of \$223,120 or a weighted average price per share of approximately \$6.94. There were two days in which transactions were conducted, and all of the shares bought back in February were cancelled. The share repurchases during the month were accretive to NBPE's NAV by approximately \$0.01 per share. As of 29 February 2012, there were 49,243,696 class A ordinary shares and 10,000 class B ordinary shares outstanding, with 3,150,408 class A ordinary shares held in treasury.

This document is not intended to be an investment advertisement or sales instrument; it constitutes neither an offer nor an attempt to solicit offers for the securities described herein. This report was prepared using financial information contained in NBPE's books and records as of the reporting date. This information is believed to be accurate but has not been audited by a third party. This report describes past performance, which may not be indicative of future results. NBPE does not accept any liability for actions taken on the basis of the information provided.

NBPE is registered with the Dutch Authority for the Financial Markets as a collective investment scheme which may offer participations in The Netherlands pursuant to article 2:66 of the Financial Markets Supervision Act (Wet op het financiael toezicht). All investments are subject to risk. Past performance is no guarantee of future returns. Prospective investors are advised to seek expert legal, financial, tax and other professional advice before making any investment decision. The value of investments may fluctuate. Results achieved in the past are no guarantee of future results.

<sup>1.</sup> Figures provided are unaudited and subject to change. Certain numbers may not total due to rounding.

<sup>2.</sup> For the NB Alternatives direct co-investment program and the NB Athyrium drug royalty investment program commitments, total exposure only reflects the funded investments to date. Unfunded amounts and unfunded percentages within each of these programs are excluded from the analysis, as capital deployment is opportunistic and cannot be accurately forecast at this time. The diversification analysis by asset class and investment type is based on the fair value of underlying fund investments and direct / co-investments (including unfunded commitments on a total private equity exposure basis). The diversification analysis by year of investment, geography and industry is based on the diversification of underlying portfolio company investments at fair value as estimated by the Investment Manager. The year of investment is calculated at the portfolio company level and is defined as the date of capital deployment into a particular underlying investment. For primary investments and direct / co-investments, the vintage year is defined as the date of the direct / co-investment. For secondary investments, the vintage year is defined as the date of the secondary acquisition. The diversification by year of investment also includes an allocation of net cash flows and valuation adjustments made since financial statements were last received from the investment sponsor. Determinations regarding asset class, investment type, geography and industry, as well as the allocation of unfunded commitments on a total private equity exposure basis, also represent the Investment Manager's estimates. Accordingly, the actual diversification of the Company's investment portfolio and the diversification of the Company's investment portfolio on an ongoing basis may vary from the foregoing information.